RAPGEFL1

Summary

RAPGEFL1 (Rap guanine nucleotide exchange factor like 1, HGNC:17428) is a protein-coding gene on chromosome 17q21.1, encoding Rap guanine nucleotide exchange factor-like 1 (Q9UHV5). Probable guanine nucleotide exchange factor (GEF).

Predicted to enable guanyl-nucleotide exchange factor activity. Predicted to be involved in Ras protein signal transduction. Predicted to be located in membrane. Predicted to be active in plasma membrane.

Source: NCBI Gene 51195 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_016339

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17428
Approved symbol	RAPGEFL1
Name	Rap guanine nucleotide exchange factor like 1
Location	17q21.1
Locus type	gene with protein product
Status	Approved
Aliases	Link-GEFII
Ensembl gene	ENSG00000108352
Ensembl biotype	protein_coding
Entrez	51195

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 3 retained_intron

ENST00000264644, ENST00000456989, ENST00000469209, ENST00000496032, ENST00000538884, ENST00000538981, ENST00000541245, ENST00000543876, ENST00000544503, ENST00000545893, ENST00000620260

RefSeq mRNA: 3 — MANE Select: NM_016339 NM_001303533, NM_001303534, NM_016339

CCDS: CCDS11363, CCDS77022, CCDS77023

Canonical transcript exons

ENST00000620260 — 15 exons

Exon	Start	End
ENSE00003460448	40191582	40191672
ENSE00003484278	40190434	40190531
ENSE00003492420	40184214	40184349
ENSE00003496506	40189208	40189375
ENSE00003502801	40192926	40192990
ENSE00003531857	40191316	40191494
ENSE00003534737	40181616	40181694
ENSE00003594024	40193363	40193417
ENSE00003602587	40192606	40192693
ENSE00003602915	40192213	40192263
ENSE00003641961	40184581	40184678
ENSE00003656787	40188866	40188978
ENSE00003681424	40190640	40190762
ENSE00003724554	40177470	40178381
ENSE00003753411	40193664	40195650

Expression profiles

Bgee: expression breadth ubiquitous, 223 present calls, max score 99.20.

FANTOM5 (CAGE): breadth broad, TPM avg 2.1867 / max 84.9471, expressed in 551 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160694	1.9628	527
160695	0.1419	80
160696	0.0820	42

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.20	gold quality
skin of abdomen	UBERON:0001416	98.80	gold quality
skin of leg	UBERON:0001511	98.77	gold quality
esophagus mucosa	UBERON:0002469	97.81	gold quality
zone of skin	UBERON:0000014	97.50	gold quality
mucosa of transverse colon	UBERON:0004991	97.49	gold quality
upper arm skin	UBERON:0004263	97.00	gold quality
right frontal lobe	UBERON:0002810	96.00	gold quality
vagina	UBERON:0000996	94.82	gold quality
tongue squamous epithelium	UBERON:0006919	94.65	gold quality
nipple	UBERON:0002030	94.47	gold quality
rectum	UBERON:0001052	94.35	gold quality
pharyngeal mucosa	UBERON:0000355	94.18	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.91	gold quality
anterior cingulate cortex	UBERON:0009835	93.82	gold quality
cingulate cortex	UBERON:0003027	93.71	gold quality
penis	UBERON:0000989	93.59	gold quality
cerebellar hemisphere	UBERON:0002245	93.33	gold quality
upper leg skin	UBERON:0004262	93.27	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.24	gold quality
cerebellar cortex	UBERON:0002129	93.20	gold quality
nucleus accumbens	UBERON:0001882	93.16	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.97	gold quality
transverse colon	UBERON:0001157	92.85	gold quality
mammalian vulva	UBERON:0000997	92.74	gold quality
prefrontal cortex	UBERON:0000451	92.35	gold quality
frontal cortex	UBERON:0001870	92.10	gold quality
neocortex	UBERON:0001950	91.79	gold quality
cerebellum	UBERON:0002037	91.56	gold quality
amygdala	UBERON:0001876	91.48	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	63.59
E-ANND-3	yes	9.26

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI2

miRNA regulators (miRDB)

116 targeting RAPGEFL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-9-3P	99.96	70.88	2068
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4447	99.85	67.81	2900

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rapgefl1	ENSDARG00000079912
mus_musculus	Rapgefl1	ENSMUSG00000038020
rattus_norvegicus	Rapgefl1	ENSRNOG00000027871

Paralogs (24): RASGRF1 (ENSG00000058335), RASGRP2 (ENSG00000068831), RAPGEF3 (ENSG00000079337), RAPGEF4 (ENSG00000091428), SOS2 (ENSG00000100485), RAPGEF1 (ENSG00000107263), RAPGEF2 (ENSG00000109756), RASGRF2 (ENSG00000113319), SOS1 (ENSG00000115904), RALGPS2 (ENSG00000116191), RAPGEF5 (ENSG00000136237), RALGPS1 (ENSG00000136828), RASGEF1B (ENSG00000138670), RGL1 (ENSG00000143344), RASGEF1C (ENSG00000146090), RASGRP3 (ENSG00000152689), RAPGEF6 (ENSG00000158987), RGL4 (ENSG00000159496), RALGDS (ENSG00000160271), RASGRP4 (ENSG00000171777), RASGRP1 (ENSG00000172575), RASGEF1A (ENSG00000198915), RGL3 (ENSG00000205517), RGL2 (ENSG00000237441)

Protein

Protein identifiers

Rap guanine nucleotide exchange factor-like 1 — Q9UHV5 (reviewed: Q9UHV5)

Alternative names: Link guanine nucleotide exchange factor II

All UniProt accessions (7): Q9UHV5, A0A087WVW6, F5GXC6, F5GY17, F5GYJ3, F5H2D5, F5H582

UniProt curated annotations — full annotation on UniProt →

Function. Probable guanine nucleotide exchange factor (GEF).

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UHV5-1	1	yes
Q9UHV5-2	2
Q9UHV5-3	3

RefSeq proteins (3): NP_001290462, NP_001290463, NP_057423* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001895	RASGEF_cat_dom	Domain
IPR008937	Ras-like_GEF	Family
IPR023578	Ras_GEF_dom_sf	Homologous_superfamily
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR036964	RASGEF_cat_dom_sf	Homologous_superfamily

Pfam: PF00617

UniProt features (20 total): strand 6, compositionally biased region 4, splice variant 3, helix 2, chain 1, domain 1, sequence conflict 1, turn 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2DHZ	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UHV5-F1	77.54	0.55

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 168 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, JAEGER_METASTASIS_DN, LHX3_01, CHX10_01, GGGTGGRR_PAX4_03, CATRRAGC_UNKNOWN, EGR1_01, GATA4_Q3, CCCNNGGGAR_OLF1_01, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, AP2_Q6_01, ATF_01, TTTGCAC_MIR19A_MIR19B, EVI1_04, TAATTA_CHX10_01

GO Biological Process (5): G protein-coupled receptor signaling pathway (GO:0007186), Ras protein signal transduction (GO:0007265), nervous system development (GO:0007399), signal transduction (GO:0007165), small GTPase-mediated signal transduction (GO:0007264)

GO Molecular Function (1): guanyl-nucleotide exchange factor activity (GO:0005085)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor activity	1
signal transduction	1
small GTPase-mediated signal transduction	1
system development	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
intracellular signaling cassette	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

486 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAPGEFL1	OGFOD3	Q6PK18	560
RAPGEFL1	SERAC1	Q96JX3	472
RAPGEFL1	LIN52	Q52LA3	446
RAPGEFL1	AMZ1	Q400G9	445
RAPGEFL1	GPRIN1	Q7Z2K8	426
RAPGEFL1	SIRAL2	Q9NWS6	424
RAPGEFL1	RNFT2	Q96EX2	421
RAPGEFL1	MAP6D1	Q9H9H5	417
RAPGEFL1	LAPTM4A	Q15012	402
RAPGEFL1	PLCE1	Q9P212	401
RAPGEFL1	RAPGEF5	Q92565	382
RAPGEFL1	ATP8B2	P98198	367
RAPGEFL1	ARHGEF4	Q9NR80	366
RAPGEFL1	WIPF2	Q8TF74	359
RAPGEFL1	GOLGA8O	A6NCC3	357

IntAct

4 interactions, top by confidence:

A	B	Type	Score
RAPGEFL1	LRPAP1	psi-mi:“MI:0915”(physical association)	0.400
RAPGEFL1	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
MLH1	RAPGEFL1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (7): RAPGEFL1 (Affinity Capture-RNA), RAPGEFL1 (Proximity Label-MS), RAPGEFL1 (Proximity Label-MS), RAPGEFL1 (Affinity Capture-RNA), RAPGEFL1 (Cross-Linking-MS (XL-MS)), APP (Reconstituted Complex), RAPGEFL1 (Two-hybrid)

ESM2 similar proteins: A0A140LI67, A0JMF6, A1L3T7, A2BGG1, A4FU01, A6NE52, D4A929, O15287, O35827, O75064, O95398, O95704, P58660, P97680, Q13671, Q3U1Y4, Q3V1L6, Q400C9, Q562E7, Q58EX7, Q5ND34, Q5PQS0, Q5RA67, Q5XIS1, Q68EF8, Q6IRN0, Q6P4K6, Q6ZNJ1, Q6ZQA0, Q76MJ5, Q7TSI1, Q80VA5, Q8CFK6, Q8IV53, Q8K330, Q8NCE2, Q8R2S1, Q8R5G7, Q8TE77, Q8VCC8

Diamond homologs: A0JM95, A4IFE4, F1M386, F1MSG6, F1PBJ0, O95398, P28818, P83900, Q02342, Q0VAM2, Q28EC1, Q5RC04, Q6DBW1, Q6DHR3, Q8C0Q9, Q8CHG7, Q8IS19, Q8JZL7, Q8MVR1, Q8N431, Q8N9B8, Q8VCC8, Q8WZA2, Q92565, Q95KH6, Q9D300, Q9EQZ6, Q9UHV5, Q9Y4G8, Q9Z1C7, Q9Z1C8, A2AR50, A2CEA7, A7A0P0, B0M0P8, B3LTF3, B5VMS9, C8ZCV7, E9Q9W7, G5EDB9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3108 predictions. Top by Δscore:

Variant	Effect	Δscore
17:40177926:G:GT	donor_gain	1.0000
17:40177926:G:T	donor_gain	1.0000
17:40178379:CAGG:C	donor_loss	1.0000
17:40178381:GGT:G	donor_loss	1.0000
17:40178382:G:A	donor_loss	1.0000
17:40178383:T:A	donor_loss	1.0000
17:40184679:G:GG	donor_gain	1.0000
17:40188974:TGAGA:T	donor_gain	1.0000
17:40188975:GAGA:G	donor_gain	1.0000
17:40188975:GAGAG:G	donor_gain	1.0000
17:40188977:GA:G	donor_gain	1.0000
17:40188978:AGT:A	donor_loss	1.0000
17:40188979:G:GG	donor_gain	1.0000
17:40188979:G:T	donor_loss	1.0000
17:40188983:GT:G	donor_gain	1.0000
17:40189206:A:AG	acceptor_gain	1.0000
17:40189207:G:GA	acceptor_gain	1.0000
17:40190528:TCTGG:T	donor_loss	1.0000
17:40190529:CTGG:C	donor_loss	1.0000
17:40190530:TGG:T	donor_loss	1.0000
17:40190532:G:GC	donor_loss	1.0000
17:40190533:T:G	donor_loss	1.0000
17:40191279:T:TA	acceptor_gain	1.0000
17:40191471:G:GT	donor_gain	1.0000
17:40191490:GCCCT:G	donor_gain	1.0000
17:40191493:CT:C	donor_gain	1.0000
17:40191493:CTGT:C	donor_loss	1.0000
17:40191494:TGTG:T	donor_loss	1.0000
17:40191495:G:GG	donor_gain	1.0000
17:40191495:GT:G	donor_loss	1.0000

AlphaMissense

4246 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:40189250:T:A	I330K	1.000
17:40190500:T:C	F394S	1.000
17:40192634:G:C	R562P	1.000
17:40192691:A:T	K581I	1.000
17:40192692:A:C	K581N	1.000
17:40192692:A:T	K581N	1.000
17:40192929:T:C	L583P	1.000
17:40192934:T:C	F585L	1.000
17:40192936:C:A	F585L	1.000
17:40192936:C:G	F585L	1.000
17:40193373:C:A	A607D	1.000
17:40181637:T:A	V181D	0.999
17:40188921:T:C	F297L	0.999
17:40188922:T:C	F297S	0.999
17:40188923:C:A	F297L	0.999
17:40188923:C:G	F297L	0.999
17:40188973:A:T	D314V	0.999
17:40189210:T:C	F317L	0.999
17:40189211:T:C	F317S	0.999
17:40189212:C:A	F317L	0.999
17:40189212:C:G	F317L	0.999
17:40189213:T:C	C318R	0.999
17:40189220:T:A	V320E	0.999
17:40189222:T:G	Y321D	0.999
17:40189237:T:C	S326P	0.999
17:40189240:T:G	Y327D	0.999
17:40189250:T:G	I330R	0.999
17:40189352:T:A	L364Q	0.999
17:40189352:T:C	L364P	0.999
17:40190467:T:A	V383D	0.999

dbSNP variants (sampled 300 via entrez): RS1000002518 (17:40175807 C>T), RS1000202385 (17:40195833 G>C), RS1000212969 (17:40179255 CAG>C), RS1000245370 (17:40179573 G>T), RS1000416605 (17:40185555 G>A), RS1000627615 (17:40193709 A>G), RS1000788987 (17:40185304 A>T), RS1000864634 (17:40191021 G>A,T), RS1000962265 (17:40181688 A>C), RS1001225420 (17:40187375 C>T), RS1001385000 (17:40192210 C>T), RS1001468104 (17:40175069 G>A), RS1001752723 (17:40191865 A>G), RS1001794343 (17:40177406 G>A), RS1001836173 (17:40176984 G>A,T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:611762

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), familial cold autoinflammatory syndrome 2 (MONDO:0012724)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NLRP12-associated hereditary periodic fever syndrome (Orphanet:247868)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST008916_85	Asthma	2.000000e-12
GCST010242_333	HDL cholesterol levels	3.000000e-13
GCST90002394_400	Monocyte percentage of white cells	2.000000e-10
GCST90002407_135	White blood cell count	5.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C567090	Familial Cold Autoinflammatory Syndrome 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases expression, increases expression	7
sodium arsenite	affects cotreatment, decreases expression, increases abundance, affects expression	4
Arsenic	decreases expression, increases abundance, affects cotreatment	3
bisphenol A	decreases methylation, increases expression	2
sodium arsenate	decreases expression, increases abundance	2
Decitabine	affects reaction, affects expression, decreases expression	2
Air Pollutants	affects expression, increases abundance, increases expression	2
Ozone	affects cotreatment, increases expression, affects expression, increases abundance	2
Smoke	decreases expression, increases abundance, increases expression	2
Genistein	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
arsenite	decreases expression, increases abundance	1
butyraldehyde	decreases expression	1
monomethylarsonic acid	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
arsenic acid	decreases expression, increases abundance	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
methacrylaldehyde	affects cotreatment, increases expression	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
mono-benzyl phthalate	increases methylation	1
monomethylarsonous acid	decreases expression	1
clothianidin	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression	1
dimethylmonothioarsinic acid	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer